In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Emraclidine was the centerpiece of AbbVie’s $8.7 billion acquisition of Cerevel in December 2023 but failed two mid-stage ...

Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

AbbVie also spoke about the disappointing data from Phase II studies of emraclidine in schizophrenia – a drug acquired as ...

AbbVie's $3.5 Billion Blow: Can Bold Bets Revive Its Profit Forecasts?

AbbVie records a $3.5 billion impairment charge following the failure of emraclidine in Phase II schizophrenia trials.

AbbVie had said it is evaluating other Cerevel-related drug development programs and will monitor the remaining intangible assets of about $3.6 billion. Sign up here. Singapore Telecommunications ...

AbbVie is still carrying over $71 billion in long-term debt from an acquisition spree that included a $63 billion purchase of Allergan, $10.1 billion for ImmunoGen, and $8.7 billion for Cerevel ...